PRO

PROS Holdings, Inc.
Inactive Not actively trading
$23.25
+0.01 (+0.02%)
Mkt Cap 1.12B
Volume 4,394,040
52W Range 13.61-29.84
Sector Technology
Beta 0.66
EPS (TTM) -0.32
P/E Ratio -51.07
Revenue (TTM) 351.68M
Rev Growth (5Y) +5.7%
EPS Growth (5Y) N/A
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
27.9 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Revenue 330.37M 303.71M 276.14M 251.42M 252.42M 250.33M 197.02M 168.82M 153.28M 168.25M 185.83M 144.84M
Net Income (20.48M) (56.35M) (82.25M) (81.21M) (76.98M) (69.08M) (64.25M) (77.93M) (75.22M) (65.81M) (36.64M) 3.45M
EPS -0.43 -1.22 -1.82 -1.83 -1.78 -1.72 -1.86 -2.46 -2.47 -2.23 -1.27 0.12
Free Cash Flow 26.22M 7.33M (24.77M) (21.35M) (79.57M) (1.51M) (510,000) (29.52M) (24.26M) 8.51M (8.05M) 10.70M
FCF / Share 0.56 0.16 -0.55 -0.48 -1.84 -0.04 -0.01 -0.93 -0.80 0.29 -0.28 0.38
Operating CF 27.38M 9.88M (23.91M) (18.55M) (49.39M) 5.25M 5.70M (25.31M) (14.35M) 15.53M 1.75M 16.97M
Total Assets 419.90M 421.83M 452.95M 494.48M 539.97M 513.31M 436.97M 288.68M 227.65M 263.72M 300.31M 179.83M
Total Debt 300.89M 324.76M 325.62M 334.78M 268.06M 140.27M 225.19M 213.20M 122.30M 116.37M 110.45M 0
Cash & Equiv 161.98M 168.75M 203.63M 227.55M 329.13M 306.08M 295.48M 160.50M 118.04M 161.77M 161.02M 44.69M
Book Value (68.70M) (77.87M) (35.47M) 3.58M 117.04M 165.00M 54.90M (46.98M) (3.39M) 55.41M 99.00M 111.30M
Return on Equity N/A N/A N/A -22.66 -0.66 -0.42 -1.17 N/A N/A -1.19 -0.37 0.03
PRO News
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
Jun 26, 2026 04:00 AM · gurufocus.com